recombinant bovine basic fibroblast growth factor
Recombinant proteinexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 21, 2018 (NCT03778008)
Timeline
Indications
Mechanism of action
- Basic fibroblast growth factorSupplementation
FGF2 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06448039 | Phase 1/Phase 2 (Phase 2) | Jun 15, 2024 | Harvard University, Nobel Pharmaceuticals |
| NCT04960384 | Phase 2 | Aug 31, 2021 | New York University |
| NCT03778008 | Phase 2 | Dec 21, 2018 | Nanchang University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Nanchang University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Nobel Pharmaceuticals | For profit | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1